Tokyo, July 8 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000058380) titled 'Prevalence of sarcopenia and respiratory sarcopenia after chimeric antigen receptor gene-modified T cell therapy' on July 7.
Study Type:
Observational
Primary Sponsor:
Institute - Hyogo Medical University
Condition:
Condition - Malignant lymphoma, multiple myeloma
Classification by malignancy - Malignancy
Genomic information - NO
Objective:
Narrative objectives1 - To investigate the prevalence of sarcopenia and respiratory sarcopenia after CAR-T cell therapy.
Basic objectives2 - Safety
Eligibility:
Age-lower limit - 18
years-old
=
Gender - Male and Female
Key inclusion criteria - Patients scheduled to undergo CAR-T cell therapy during hospitalization
Key exclusion criteria - Those with severe heart disease, lung disease, or brain or nervous system disorders; those with pacemakers; and those with other systemic conditions that are difficult to evaluate.
Target Size - 100
Recruitment Status:
Recruitment status - Enrolling by invitation
Date of protocol fixation - 2025 Year 06 Month 01 Day
Date of IRB - 2025 Year 04 Month 15 Day
Anticipated trial start date - 2025 Year 06 Month 01 Day
Last follow-up date - 2030 Year 06 Month 30 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000066743
Disclaimer: Curated by HT Syndication.
